ABSI
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Absci Corporation
- Nom
- Absci Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.6B
- Employés
- 140
- PDG
- Sean McClain
- Site web
- https://www.absci.com
- Marché
- ABCLGENB
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 12900 titres (~148866 USD)
- Insiders
- Szela Mary T
- Total bought
-
$148,866
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-06-30
- Last synced
-
2026-10-19 22:33:27
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
ABSI presents a conflicted profile: a genuine Phase I clinical catalyst (ABSI-201 hair loss data) supported by an insider purchase post-surge lends short-term event-driven interest, but the fundamental backdrop is…
The first sentence of the analysis written for ABSI on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 6.57 · operating margin -4454% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -319.4% | -1277.6% | -731.9% | -925.0% | -832.4% | |
| Ebit Margin | -4103.8% | -2370.7% | -1638.3% | -1816.5% | -1554.5% | |
| Ebitda Margin | -3684.4% | -2075.4% | -1393.5% | -1588.5% | -1415.4% | |
| Operating Profit Margin | -4454.2% | -2401.6% | -2020.2% | -1857.5% | -1573.4% | |
| Pretax Profit Margin | -4111.2% | -2272.5% | -1931.9% | -1833.4% | -2297.3% | |
| Continuous Operations Profit Margin | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | |
| Net Profit Margin | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | |
| Bottom Line Profit Margin | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2159.0% | |
| Current Ratio | 6.570 | 4.670 | 4.079 | 6.173 | 8.065 | |
| Quick Ratio | 6.570 | 4.670 | 4.079 | 5.677 | 7.755 | |
| Solvency Ratio | -3.853 | -2.602 | -2.348 | -1.970 | -1.569 | |
| Cash Ratio | 0.880 | 1.438 | 2.448 | 1.981 | 7.459 | |
| Price To Earnings Ratio | -4.155 | -2.787 | -3.500 | -1.826 | -7.387 | |
| Price To Earnings Growth Ratio | 0.391 | 0.129 | -0.805 | -0.507 | -0.070 | |
| Forward Price To Earnings Growth Ratio | 0.391 | 0.129 | -0.805 | -0.507 | -0.070 | |
| Price To Earnings Diluted Ratio | -4.155 | -2.787 | -3.500 | -1.826 | -7.387 | |
| Price To Earnings Diluted Growth Ratio | 0.391 | 0.129 | -0.805 | -0.507 | -0.070 | |
| Price To Book Ratio | 2.520 | 1.612 | 2.194 | 0.695 | 2.075 | |
| Price To Sales Ratio | 170.483 | 63.703 | 67.597 | 33.196 | 158.869 | |
| Price To Free Cash Flow Ratio | -5.076 | -3.967 | -5.901 | -1.956 | -7.701 | |
| Price To Operating Cash Flow Ratio | -5.137 | -3.989 | -5.980 | -2.345 | -12.537 | |
| Debt To Assets Ratio | 0.025 | 0.047 | 0.073 | 0.072 | 0.047 | |
| Debt To Equity Ratio | 0.028 | 0.056 | 0.090 | 0.084 | 0.055 | |
| Debt To Capital Ratio | 0.027 | 0.053 | 0.083 | 0.077 | 0.052 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.007 | 0.026 | 0.028 | 0.003 | |
| Financial Leverage Ratio | 1.142 | 1.192 | 1.233 | 1.170 | 1.164 | |
| Working Capital Turnover Ratio | 0.024 | 0.046 | 0.046 | 0.029 | 0.032 | |
| Operating Cash Flow Ratio | -4.082 | -2.527 | -2.187 | -2.687 | -1.790 | |
| Operating Cash Flow Sales Ratio | -33.188 | -15.969 | -11.304 | -14.153 | -12.672 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.012 | 1.006 | 1.013 | 1.199 | 1.628 | |
| Debt Service Coverage Ratio | -95.409 | -28.553 | -18.693 | -23.183 | -10.080 | |
| Interest Coverage Ratio | -596.737 | -192.722 | -114.371 | -109.825 | -21.922 | |
| Short Term Operating Cash Flow Coverage Ratio | -106.443 | -26.492 | -19.839 | -27.610 | -25.249 | |
| Operating Cash Flow Coverage Ratio | -17.526 | -7.165 | -4.070 | -3.539 | -3.028 | |
| Capital Expenditure Coverage Ratio | -83.943 | -179.213 | -75.158 | -5.029 | -1.593 | |
| Dividend Paid And Capex Coverage Ratio | -83.943 | -179.213 | -75.158 | -5.029 | -1.593 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.484 | -2.739 | -4.142 | -1.685 | -7.788 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -319.4% | ▲958.2% | ▲497.9% |
| Ebit Margin | -4103.8% | ▼-1733.0% | ▼-1807.0% |
| Ebitda Margin | -3684.4% | ▼-1609.0% | ▼-1652.9% |
| Operating Profit Margin | -4454.2% | ▼-2052.6% | ▼-1992.8% |
| Pretax Profit Margin | -4111.2% | ▼-1838.7% | ▼-1621.9% |
| Continuous Operations Profit Margin | -4113.7% | ▼-1839.6% | ▼-1662.1% |
| Net Profit Margin | -4113.7% | ▼-1839.6% | ▼-1662.1% |
| Bottom Line Profit Margin | -4113.7% | ▼-1839.6% | ▼-1652.5% |
| Current Ratio | 6.570 | ▲1.900 | ▲0.659 |
| Quick Ratio | 6.570 | ▲1.900 | ▲0.820 |
| Solvency Ratio | -3.853 | ▼-1.250 | ▼-1.384 |
| Cash Ratio | 0.880 | ▼-0.559 | ▼-1.962 |
| Price To Earnings Ratio | -4.155 | ▼-1.367 | ▼-0.224 |
| Price To Earnings Growth Ratio | 0.391 | ▲0.262 | ▲0.563 |
| Forward Price To Earnings Growth Ratio | 0.391 | ▲0.262 | ▲0.563 |
| Price To Earnings Diluted Ratio | -4.155 | ▼-1.367 | ▼-0.224 |
| Price To Earnings Diluted Growth Ratio | 0.391 | ▲0.262 | ▲0.563 |
| Price To Book Ratio | 2.520 | ▲0.907 | ▲0.700 |
| Price To Sales Ratio | 170.483 | ▲106.780 | ▲71.713 |
| Price To Free Cash Flow Ratio | -5.077 | ▼-1.109 | ▼-0.156 |
| Price To Operating Cash Flow Ratio | -5.137 | ▼-1.148 | ▲0.861 |
| Debt To Assets Ratio | 0.025 | ▼-0.023 | ▼-0.028 |
| Debt To Equity Ratio | 0.028 | ▼-0.028 | ▼-0.035 |
| Debt To Capital Ratio | 0.027 | ▼-0.026 | ▼-0.031 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.007 | ▼-0.013 |
| Financial Leverage Ratio | 1.142 | ▼-0.051 | ▼-0.039 |
| Working Capital Turnover Ratio | 0.024 | ▼-0.022 | ▼-0.011 |
| Operating Cash Flow Ratio | -4.082 | ▼-1.555 | ▼-1.427 |
| Operating Cash Flow Sales Ratio | -33.188 | ▼-17.219 | ▼-15.730 |
| Free Cash Flow Operating Cash Flow Ratio | 1.012 | ▲0.006 | ▼-0.160 |
| Debt Service Coverage Ratio | -95.409 | ▼-66.855 | ▼-60.225 |
| Interest Coverage Ratio | -596.737 | ▼-404.015 | ▼-389.621 |
| Short Term Operating Cash Flow Coverage Ratio | -106.443 | ▼-79.951 | ▼-65.317 |
| Operating Cash Flow Coverage Ratio | -17.526 | ▼-10.361 | ▼-10.461 |
| Capital Expenditure Coverage Ratio | -83.943 | ▲95.270 | ▼-14.956 |
| Dividend Paid And Capex Coverage Ratio | -83.943 | ▲95.270 | ▼-14.956 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.484 | ▼-1.746 | ▼-0.317 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $477.4M | $288.8M | $386.5M | $190.8M | $759.7M | |
| Enterprise value | $462.6M | $257.7M | $330.0M | $153.8M | $527.2M | |
| EV / Sales | 165.22x | 56.84x | 57.72x | 26.76x | 110.24x | |
| EV / Op. cash flow | -4.98x | -3.56x | -5.11x | -1.89x | -8.70x | |
| EV / Free cash flow | -4.92x | -3.54x | -5.04x | -1.58x | -5.34x | |
| EV / EBITDA | -4.48x | -2.74x | -4.14x | -1.69x | -7.79x | |
| Net debt / EBITDA | 0.14x | 0.33x | 0.71x | 0.41x | 3.44x | |
| Current ratio | 6.57x | 4.67x | 4.08x | 6.17x | 8.06x | |
| Income quality | 0.81x | 0.70x | 0.58x | 0.78x | 0.60x | |
| Graham net-net | $1 | $1 | $1 | $1 | $2 | |
| Tax burden | 100.1% | 100.1% | 100.1% | 99.6% | 91.9% | |
| Interest burden | 100.2% | 95.9% | 117.9% | 100.9% | 147.8% | |
| Working capital | $126.8M | $105.2M | $91.0M | $156.6M | $239.2M | |
| Invested capital | $192.1M | $183.2M | $185.1M | $287.6M | $374.2M | |
| Return on assets | -53.3% | -48.3% | -50.9% | -32.7% | -23.7% | |
| Operating ROA | -58.0% | -50.5% | -42.9% | -28.6% | -29.2% | |
| Return on tangible assets | -65.9% | -61.1% | -65.4% | -42.3% | -28.9% | |
| Return on equity | -60.8% | -57.6% | -62.8% | -38.2% | -27.6% | |
| Return on invested capital | -63.6% | -57.5% | -59.8% | -35.7% | -17.3% | |
| Return on capital employed | -64.4% | -58.9% | -61.5% | -36.7% | -19.2% | |
| Earnings yield | -24.1% | -35.7% | -28.6% | -55.0% | -13.3% | |
| Free cash flow yield | -19.7% | -25.2% | -16.9% | -51.1% | -13.0% | |
| Capex / Op. cash flow | -1.2% | -0.6% | -1.3% | -19.9% | -62.8% | |
| Capex / Depreciation | 9.4% | 3.0% | 6.1% | 123.5% | 571.8% | |
| Capex / Sales | 39.5% | 8.9% | 15.0% | 281.5% | 795.6% | |
| SG&A / Sales | 1252.1% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 2907.8% | 1408.4% | 840.6% | 1025.0% | 932.4% | |
| Stock comp / Sales | 654.3% | 429.0% | 199.7% | 218.2% | 221.8% | |
| Intangibles / Total assets | 19.2% | 21.0% | 22.2% | 22.7% | 17.9% | |
| Days sales outstanding | 0d | 0d | 140d | 98d | 109d | |
| Days payables outstanding | 86d | 21d | 12d | 15d | 69d | |
| Operating cycle | 0d | 0d | 140d | 192d | 195d | |
| Cash conversion cycle | -86d | -21d | 128d | 177d | 126d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+65.3%EV / Sales ▲+190.7%EV / EBITDA ▼-63.7%EV / Op. cash flow ▼-1.419Earnings yield ▲+0.116
Profitability
Return on equity ▼-0.032Return on assets ▼-0.050Return on invested capital ▼-0.061Return on capital employed ▼-0.056Operating ROA ▼-0.075Income quality ▲+0.105Tax burden -0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+65.047Operating cycle n/aCash conversion cycle ▼-65.047Capex / Sales ▲+0.306R&D / Sales ▲+14.993
Balance-sheet strength
Current ratio ▲+1.900Net debt / EBITDA ▼-0.188Working capital ▲+21633000.000Invested capital ▲+8903000.000Intangibles / Total assets ▼-0.018
Change over 5 years
Valuation
Market cap ▼-37.2%EV / Sales ▲+49.9%EV / EBITDA ▲+42.4%EV / Op. cash flow ▲+3.721Earnings yield ▼-0.108
Profitability
Return on equity ▼-0.332Return on assets ▼-0.296Return on invested capital ▼-0.462Return on capital employed ▼-0.453Operating ROA ▼-0.288Income quality ▲+0.207Tax burden ▲+0.082
Efficiency
Days sales outstanding ▼-108.767Days payables outstanding ▲+17.027Operating cycle ▼-194.831Cash conversion cycle ▼-211.858Capex / Sales ▼-7.561R&D / Sales ▲+19.754
Balance-sheet strength
Current ratio ▼-1.495Net debt / EBITDA ▼-3.293Working capital ▼-112412000.000Invested capital ▼-182103000.000Intangibles / Total assets ▲+0.013
Employee count
Peer market caps
Recent news
- 2026-10-13 Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026 VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.
- 2026-10-08 Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX) Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Insider and Institutional Ownership 95.5% of Black
- 2026-09-24 Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.
- 2026-09-21 Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Risk and Volatility Silence Therapeutics has a beta
- 2026-09-21 Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN) Valneva (NASDAQ: VALN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Profitability This table compares Valneva and Absci''s net margins,
- 2026-09-16 Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-08 Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade) Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
- 2026-09-04 Absci Corporation $ABSI Shares Bought by Bank of America Corp DE Bank of America Corp DE raised its holdings in Absci Corporation (NASDAQ: ABSI) by 55.2% in the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 487,193 shares of the company''s stock after acquiring an additional 173,361 shares during the period. Bank of America Corp DE owned
- 2026-09-01 Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Sept.
- 2026-08-18 AMD''s $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next On August 14, 2026, Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) filed its first-ever 13F, pulling back the curtain on a $1.31 billion equity portfolio concentrated in just six positions.